Latest News & Updates

FDA approves rituximab plus chemotherapy for pediatric cancer indications
December 3, 2021

Continue Reading »

FDA approves Darzalex Faspro, Kyprolis, and Dexamethasone for Multiple Myeloma
December 1, 2021

Continue Reading »

FDA approves sirolimus protein-bound particles for malignant perivascular epithelioid cell tumor
November 23, 2021

Continue Reading »

FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia
October 29, 2021

Continue Reading »

FDA approves rituximab plus chemotherapy for pediatric cancer indications
December 3, 2021

Continue Reading »

FDA approves Darzalex Faspro, Kyprolis, and Dexamethasone for Multiple Myeloma
December 1, 2021

Continue Reading »

FDA approves sirolimus protein-bound particles for malignant perivascular epithelioid cell tumor
November 23, 2021

Continue Reading »

FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia
October 29, 2021

Continue Reading »

Get More from FLASCO With Your Membership

The Corporate Membership Program allows FLASCO to expand our offerings to our membership. Every FLASCO meeting also provides the industry representative with opportunities to educate our members. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together.

Corporate Members:

Diamond Elite

Diamond

Platinum

Gold

We're Here to Help Contact Us

Contact Us

Add your name, email & message below: